Security key
29286M113
enGene Therapeutics Inc. - *W EXP 10/31/202 (ENGNW)
CUSIP: 29286M113
Q1 2026 13F Holders as of 31 Mar 2026
- Security type / class
- Equity / *W EXP 10/31/202
- Total 13F shares
- 5,053,795
- Total 13F value
- $12,919,892
- Share change
- +208,437
- SEC-reported price per share
- $2.53
- Number of holders
- 11
- Value change
- +$322,528
- Number of buys
- 4
- Number of sells
- 6
Report period
Q1 2026
Institutions
11
Top holders
10
ENGNW full security history
Ownership snapshot
Full 13F holder table
enGene Therapeutics Inc. SEC filings
enGene Therapeutics Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of ENGNW - enGene Therapeutics Inc. - *W EXP 10/31/202 (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
PERCEPTIVE ADVISORS LLC
Disclosed value leader
PERCEPTIVE ADVISORS LLC
Comparable rows
15/15
Latest evidence
31 Mar 2026
13F
13D/G
3/4/5
Lead comparable stake: 10%
13D/G row: PERCEPTIVE ADVISORS LLC
Showing 1-6 of 15 holder rows.
Quick read
PERCEPTIVE ADVISORS LLC leads the comparable SEC ownership view at 10%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens PERCEPTIVE ADVISORS LLC's linked filing trail.
Comparable ownership
Top 5
PERCEPTIVE ADVISORS LLC
10%
Invus Global Management, LLC
7.8%
Venrock Healthcare Capital Partne...
7.1%
Deep Track Capital, LP
6.7%
Fonds de solidarite des travaille...
4.5%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC |
13F
13D/G
Company
|
10%
from 13D/G
|
$52,997,756
5,869,076 shares
|
— | 31 Dec 2025 |
| Invus Global Management, LLC |
13D/G
Raymond Debbane
|
7.8%
|
$35,511,355
5,253,159 shares
|
+$6,818,136 | 31 Mar 2026 |
| Venrock Healthcare Capital Partners III, L.P. |
13D/G
|
7.1%
|
$39,984,449
4,771,414 shares
|
-$2,304,500 | 31 Dec 2025 |
| Deep Track Capital, LP |
13F
13D/G
Company
|
6.7%
from 13D/G
|
$39,529,475
4,377,572 shares
|
— | 31 Dec 2025 |
| Fonds de solidarite des travailleurs et des travailleuses du Quebec |
3/4/5
13D/G
10%+ Owner
|
4.5%
from 13D/G
|
$45,542,295
3,036,153 shares
|
— | 18 Apr 2024 |
| Adage Capital Management, L.P. |
13D/G
|
3%
|
$6,115,072
1,528,768 shares
|
$0 | 31 Dec 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
11
Shares
5,053,795
Rows available
11
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2026 vs Q1 2026 Across Filers
Q1 2026 holders
11
Q1 2026 holders
11
Holder diff
0
| Investor | Q1 2026 Shares | Q1 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q1 2026 value | Value change | Value Chg % |
|---|